Trial Profile

Phase 1 Clinical Trial of Lysergic Acid Diethylamide Microdosing in 80 Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lysergic acid diethylamide MindBio Therapeutics (Primary)
Indications Major depressive disorder
Focus Adverse reactions

Most Recent Events

01 May 2024 According to a MindBio Therapeutics media release, company will publish further readouts of this Phase 1 study results in 2024.
05 Sep 2023 Topline Results presented in MindBio Therapeutics Media Release.
05 Sep 2023 According to MindBio Therapeutics media release, company reports it has made a major discovery from genetic testing clinical patients in its LSD-microdose trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com